Take the Diabetes Health Pump Survey
See What's Inside
Read this FREE issue now
For healthcare professionals only
  • 12 Tips for Traveling With Diabetes
See the entire table of contents here!

You can view the current or previous issues of Diabetes Health online, in their entirety, anytime you want.
Click Here To View

See if you qualify for our free healthcare professional magazines. Click here to start your application for Pre-Diabetes Health, Diabetes Health Pharmacist and Diabetes Health Professional.

Learn More About the Professional Subscription

Free Diabetes Health e-Newsletter
Latest
Popular
Top Rated
Diabetes Archives
Print | Email | Share | Comments (0)

Rheumatoid Arthritis Drug Drops A1c


May 16, 2007

A drug initially designed to treat the autoimmune disease of juvenile rheumatoid arthritis has been found helpful in treating type 2 diabetes.  The drug is an “interleukin-1-receptor antagonist” that goes by the name of anakinra (Kineret).

Interleukins are a type of cytokine, special messenger proteins that communicate between cells. The message sent by interleukin-1 (IL-1) triggers action by disease-fighting cells that, in diabetes and rheumatoid arthritis, are misguided and cause inflammation.  Anakinra is “antagonistic” to the IL-1 receptor; that is, it keeps IL-1 from binding to its receptor on the cell at the receiving end of the message.  If IL-1 can’t bind, the message doesn’t get through. Anakinra binds to the same receptor on the cell as IL-1 ordinarily would. By hogging the spot and keeping IL-1 from sending its signal to that cell, it stops IL-1 from triggering inflammation.

High glucose concentrations increase the production of a certain interleukin, IL-1 beta. IL-1 beta causes impaired insulin secretion, decreased beta cell growth, and beta cell death. Furthermore, natural IL-1 receptor antagonist is reduced in the islets of people with type 2 diabetes. The upshot is that you’ve got too much IL-beta and too little IL-1 receptor antagonist, resulting in inflammation and beta cell destruction.

In the Swiss study, a thirteen-week treatment of daily injections of anakinra increased insulin production and led to a 0.33% drop in A1c’s in 34 people with type 2 diabetes.  The A1c’s of the control group increased 0.13%. The researchers theorize that the drop was due to enhanced beta cell secretory function. Oddly enough, the drug was more effective in thinner people.

Forbes.com
The New England Journal of Medicine


Categories: A1c Test, Diabetes, Diabetes, Insulin, Medications, Type 2 Issues, Type 2 Medications



You May Also Be Interested In...


Comments


Add your comments about this article below. You can add comments as a registered user or anonymously. If you choose to post anonymously your comments will be sent to our moderator for approval before they appear on this page. If you choose to post as a registered user your comments will appear instantly.

When voicing your views via the comment feature, please respect the Diabetes Health community by refraining from comments that could be considered offensive to other people. Diabetes Health reserves the right to remove comments when necessary to maintain the cordial voice of the diabetes community.

For your privacy and protection, we ask that you do not include personal details such as address or telephone number in any comments posted.

Don't have your Diabetes Health Username? Register now and add your comments to all our content.

Have Your Say...


Username: Password:
Comment:
©1991-2014 Diabetes Health | Home | Privacy | Press | Advertising | Help | Contact Us | Donate | Sitemap

Diabetes Health Medical Disclaimer

The information on this site is not intended or implied to be a substitute for professional medical advice, diagnosis or treatment. All content, including text, graphics, images, and information, contained on or available through this website is for general information purposes only. Opinions expressed here are the opinions of writers, contributors, and commentators, and are not necessarily those of Diabetes Health. Never disregard professional medical advice or delay seeking medical treatment because of something you have read on or accessed through this website.